Morphotek, Inc.

Morphotek announces research collaboration and license agreement with Novo Nordisk for improvements to a protein process of a marketed therapeutic protein

Morphotek announces research collaboration and license agreement with Novo Nordisk for improvements to a protein process of a marketed therapeutic protein

July 7, 2003

Exton, Pa, July 7, 2003 - Morphotek, Inc. today announced that it has entered into a Research Collaboration and License Agreement with Novo Nordisk (NYSE: NVO) for the use of Morphotek's MORPHODOMA™ and DIRECT-LINE® technology to make significant improvements to a protein process of a marketed Novo Nordisk therapeutic protein.

Hypnion, Inc.

Hypnion founders elected to National Academy of Sciences

Hypnion founders elected to National Academy of Sciences

July 8, 2003

Elections represent highest honors accorded U.S. scientists, underscore significance of company's scientific research and developments in chronic sleep-wake disorders

From dBusinessNews.com, July 8, 2003

WORCESTER - Hypnion, Inc., a pioneering neuroscience drug discovery company focused on sleep-wake neurobiology and pharmaceuticals, today announced that two of its founders - Michael Rosbash and Joseph S. Takahashi - have been elected to the National Academy of Sciences (NAS).

Affinnova, Inc.

Design software firm Affinnova sees $6M Series B

Design software firm Affinnova sees $6M Series B

July 9, 2003

By Estee Pierce of VentureWire, July 9, 2003

CAMBRIDGE, Mass. - Affinnova, a developer of software that applies genetic algorithm technologies for use in consumer product design, is expected to announced that it has raised $6 million in a Series B round financing. Lead investor Flagship Ventures provided the full sum of the round, and is the sole outside shareholder in Affinnova. The company was founded in 2000 as an incubator company of NewcoGen Group, which is part of Flagship's family of funds along with OneLiberty, also a past investor in Affinova.

Affinnova, Inc.

Affinnova adds $6 million in B round from Flagship Ventures

Affinnova adds $6 million in B round from Flagship Ventures

July 9, 2003

Cambridge, Mass. - July 9, 2003 - Affinnova, a leading provider of product design, development, and testing solutions, announced today that it has completed a $6 million Series B round of financing led by Flagship Ventures. This latest financing round is expected to accelerate the market penetration of Affinnova's solutions coming on the heels of a six-month period when the Company recorded revenue growth of more than 120% over prior year.

EXACT Sciences

Exact Sciences reaches $15 million milestone

Exact Sciences reaches $15 million milestone

August 13, 2003

Exact Sciences Corp. of Marlborough said it has achieved the $15 million milestone associated with the national commercial availability of PreGen-Plus, which is intended for early detection of colorectal cancer.

This is the second $15 million milestone achieved in connection with the licensing agreement Exact Sciences and Laboratory Corp. of America Holdings entered into in June 2002. PreGen-Plus is Exact Sciences' proprietary DNA-based stool assay for the early detection of colorectal cancer.

Renovis

Renovis raises $45.0 million in private placement

Renovis raises $45.0 million in private placement

August 11, 2003

South San Francisco, California - August 11, 2003 - Renovis, a biopharmaceutical company focused on the discovery and development of drugs to treat neurological diseases and disorders, announced today the completion of its Series E Preferred Stock financing totaling $45.0 million. Easton Hunt Capital Partners led the financing, which included first-time investments from HealthCap, MDS Capital, Invus Group, CDIB BioScience Ventures, and others.

Carbon Design Systems

Introducing Carbon Design Systems, EDA company formed to solve the system validation problem

Introducing Carbon Design Systems, EDA company formed to solve the system validation problem

September 2, 2003

Carbon Design Systems announced today that it is delivering software products that enable system validation of hardware and software in an enterprise-wide environment. For the first time, critical software - drivers, firmware, and diagnostics - runs at KHz execution speed on the 'golden' RTL hardware model with cycle and register accuracy. This enables system and customer validation to occur much earlier than traditional methods. The Company also announced that it has raised over $5 million in funding from Boston-based Flagship Ventures and Commonwealth Capital.

Selventa

Genstruct Completes $6.5 Million Series A Financing

Genstruct Completes $6.5 Million Series A Financing

September 8, 2003

CAMBRIDGE, Mass. September 8, 2003 - Genstruct, a biological-mechanism discovery company, today announced the completion of $6.5M in Series A financing co-led by A. M. Pappas and Associates (Research Triangle Park, NC) and Flagship Ventures (Cambridge, MA). These funds will be used to expand Genstruct's technical and business teams, build intellectual property around the company's enabling technology, and conduct internal discovery programs. As a result of the financing, Art Pappas, Managing Partner of A. M. Pappas and Associates, has joined Genstruct's Board of Directors.

CGI Pharmaceuticals, Inc.

Cellular Genomics wins European patent for kinase technology

Cellular Genomics wins European patent for kinase technology

September 16, 2003

Branford, Conn.-based Cellular Genomics Inc. today announced that the European Patent Office has granted the company a patent that covers general methods for discovering enzyme inhibitors, as well as methods and compositions of a class of specific inhibitors of protein kinases, a major class of drug targets.
CGI was granted a U.S. patent for the same technology in May 2002.

Zalicus

CombinatoRx CEO named Innovator of the Year

CombinatoRx CEO named Innovator of the Year

September 25, 2003

Alexis Borisy honored by Technology Review, MIT's Magazine of Innovation, at the Emerging Technologies Conference